Intellia's in vivo CRISPR therapy hits Phase 3 for hereditary angioedema, signaling a potential one-time treatment
TL;DR Summary
Intellia Therapeutics said its one-time, in vivo CRISPR-based treatment for hereditary angioedema met its Phase 3 primary endpoint, reducing attacks by 87% vs placebo and achieving 62% attack-free patients at six months after a liver-directed infusion, with a favorable safety profile. The company has started a rolling FDA submission and targets a U.S. launch in 2027 if approved.
- Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial CNBC
- Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Intellia Therapeutics
- Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 Yahoo Finance
- Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial statnews.com
- Intellia Therapeutics Initiates Rolling Submission of GlobeNewswire
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
3 min
vs 4 min read
Condensed
91%
644 → 58 words
Want the full story? Read the original article
Read on CNBC